Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Douglas Weckstein"'
Autor:
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P. Winer, Ian Krop, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with
Externí odkaz:
https://doaj.org/article/e88fcc1488804534afd42026e28dc869
Autor:
Paolo Tarantino, Nabihah Tayob, Chau T Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, Paul K. Marcom, Kathy S. Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Kathryn Ruddy, Yue Zheng, Romualdo Barroso-Sousa, Adrienne Waks, Michelle K. DeMeo, Molly K. DiLullo, Giuseppe Curigliano, Harold Burstein, Ann Partridge, Eric Winer, Giuseppe Viale, Winnie Hui, Elizabeth A. Mittendorf, Bryan P. Schneider, Aleix Prat, Ian Krop, Sara Tolaney
Publikováno v:
Cancer Research. 83:PD18-01
Background: The ATEMPT trial primary analysis found that one year of adjuvant trastuzumab emtansine (T-DM1) achieved a 3-year iDFS of 97.8% for patients with stage I HER2+ breast cancer, but was not associated with fewer clinically relevant toxicitie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85dc5c0c6947eee6406ca29989d747df
https://doi.org/10.1158/1538-7445.sabcs22-pd18-01
https://doi.org/10.1158/1538-7445.sabcs22-pd18-01
Autor:
P. Kelly Marcom, Ann H. Partridge, Hope S. Rugo, Ron Bose, Denise A. Yardley, Douglas Weckstein, Katherine E. Reeder-Hayes, Harold J. Burstein, Michael Constantine, Rita Nanda, Jiani Hu, Patricia DeFusco, Nadine Tung, William T. Barry, Ian E. Krop, Chau T. Dang, Bhuvaneswari Ramaswamy, Frederick Briccetti, Vijayakrishna K. Gadi, V. Valero, Lorenzo Trippa, Sara M. Tolaney, Kit L. Cheng, Eric P. Winer, Antonio C. Wolff, Lowell L. Hart, Michelle Demeo, Blair Ardman, Steven J. Isakoff, Bryan P. Schneider, Kathryn J. Ruddy, Therese M. Mulvey, Rachel C. Jankowitz, Meredith Faggen, Dan Sayam Zuckerman, Kathy S. Albain, A. Merrill Garrett
Publikováno v:
Cancer Research. 80:P2-13
Background: CRA is a surrogate for ovarian toxicity and associated risk of infertility and long-term menopausal symptoms. Therefore, it is important to assess and report the rate of CRA when we study a new neoadjuvant treatment regimen. In the Adjuva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15d0d297ed01e27f0feaa7d331abee35
https://doi.org/10.1158/1538-7445.sabcs19-p2-13-02
https://doi.org/10.1158/1538-7445.sabcs19-p2-13-02
Autor:
Lowell L. Hart, Michelle Demeo, Minetta C. Liu, P. Kelly Marcom, Ron Bose, Douglas Weckstein, Ann H. Partridge, Blair Ardman, A. Merrill Garrett, Rita Nanda, Catherine Van Poznak, Andres Forero-Torres, Vicente Valero, Hope S. Rugo, Jiani Hu, Dan Sayam Zuckerman, Yue Zheng, Sara M. Tolaney, Eric P. Winer, Nabihah Tayob, Katherine E. Reeder-Hayes, Kit Cheng, Harold J. Burstein, Chau T. Dang, Patricia DeFusco, Vijayakrishna K. Gadi, Ian E. Krop, Therese M. Mulvey, Bryan P. Schneider, Rachel C. Jankowitz, Mothaffar F. Rimawi, Frederick Briccetti, Shoshana M. Rosenberg, Kathryn J. Ruddy, Nadine Tung, Vandana G. Abramson, Steven J. Isakoff, Tal Sella, Meredith Faggen, Bhuvaneswari Ramaswamy, Antonio C. Wolff, Paula R. Pohlmann, Michael Constantine, Kathy S. Albain, Denise A. Yardley
Publikováno v:
Breast cancer research and treatment. 189(1)
Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause. Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with ado-trastuzumab emtansine (T-DM1). Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f951bc6f1e660e452ab3f630355206e
https://pubmed.ncbi.nlm.nih.gov/34120223
https://pubmed.ncbi.nlm.nih.gov/34120223
Autor:
Thomas A. Abrams, Jennifer A. Chan, Justin C. Brown, Sui Zhang, Michael H. Rosenthal, Matthew B. Yurgelun, Brian M. Wolpin, Emily Chan, Halla Sayed Nimeiri, Chryssanthi Kournioti, Hui Zheng, Deborah Schrag, Jeffrey A. Meyerhardt, Michael Constantine, Nadine Jackson McCleary, James M. Cleary, Chao Ma, Andrea J. Bullock, Charles S. Fuchs, Douglas Weckstein, Chen Yuan, Meredith A. Faggen, Jill N. Allen, Kimmie Ng, Bruce W. Hollis, Christian Thomas, Dan Sayam Zuckerman, Douglas A. Rubinson
Publikováno v:
Cancers
Volume 12
Issue 11
Cancers, Vol 12, Iss 3451, p 3451 (2020)
Volume 12
Issue 11
Cancers, Vol 12, Iss 3451, p 3451 (2020)
Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22be4271bec37e6fc06cfa2803e457bd
Autor:
Erik Asmus, Claudine Isaacs, Donald B. Wender, Lauren J. Rogak, Ethan Basch, Bret Edward Buckley Friday, DeQuincy Andrew Lewis, Thomas H. Openshaw, Gini F. Fleming, Alvaro Moreno-Aspitia, Amylou C. Dueck, Minetta C. Liu, Kendrith M. Rowland, Nguyet A. Le-Lindqwister, Alan P. Lyss, Ashley Frith, John T. Cole, Anthony J. Jaslowski, Douglas Weckstein, David W. Hillman
Publikováno v:
Journal of Clinical Oncology. 38:1016-1016
1016 Background: The ph III EMBRACE trial of E vs physician’s choice of tx led to FDA approval of E as ≥3rd-line tx for MBC pts with prior exposure to anthracyclines/taxanes. The ph III BOLD 301 trial of E vs capecitabine in advanced BC treated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e71bf43f76db7bbccf5c0151772ab159
https://doi.org/10.1200/jco.2020.38.15_suppl.1016
https://doi.org/10.1200/jco.2020.38.15_suppl.1016
Autor:
Douglas A. Rubinson, Matthew B. Yurgelun, Jeffrey A. Meyerhardt, Kimmie Ng, Meredith Gail Faggen, Douglas Weckstein, Deborah Schrag, Erica N. Heying, Tanios Bekaii-Saab, Marla Lipsyc-Sharf, Samantha R Schuetz, Fang-Shu Ou, Philip J. Stella, Shaker R. Dakhil, Stephanie Noble, Donald B. Wender, Charles S. Fuchs, Tyler Zemla
Publikováno v:
Journal of Clinical Oncology. 38:102-102
102 Background: Combination irinotecan and cetuximab is approved for irinotecan-refractory mCRC; it is unknown if the addition of bevacizumab would improve outcomes. We studied the efficacy and safety of CBI compared with CI in patients (pts) with RA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d4cd571e6a85a9aa77163bd9f6d76f5
https://doi.org/10.1200/jco.2020.38.4_suppl.102
https://doi.org/10.1200/jco.2020.38.4_suppl.102
Autor:
Douglas Weckstein, Pamela J. Atherton, Lori M. Minasian, Ethan Basch, William M. Sikov, Ann M. O'Mara, Rachel A. Freedman, William Kevin Kelly, Lisa A. Carey, Hope S. Rugo, Andrew L. Himelstein, Maura N. Dickler, Charles S. Kuzma, Jeffrey J. Kirshner, Drew K. Seisler, Electra D. Paskett, Rebecca S. Heist, Amylou C. Dueck, Andrea Denicoff, Lauren J. Rogak, Alan P. Venook, Deborah Schrag, Mark A. Socinski, David D. Biggs, Diana Lake
Publikováno v:
JAMA oncology, vol 3, iss 8
IMPORTANCE: In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reported by investigators rather than by patients. There is increasing interest to collect symptomatic AE data via patient-reported outcome (PRO) questionnai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222a31a0999c24bfd3b99311e6bfbecb
Autor:
Stephen DeSantis, Harold J. Burstein, Davinia Shien Seah, Nan Lin, Pamela J. DiPiro, Steven E. Come, Eric P. Winer, Douglas Weckstein, Steven J. Isakoff, Rebecca Gelman, Erica L. Mayer, Ian E. Krop
Publikováno v:
Breast Cancer Research and Treatment. 139:403-410
We aimed to evaluate the efficacy and feasibility of combining trastuzumab/vinorelbine with bevacizumab in patients with first-or second-line HER2-positive, metastatic breast cancer (MBC). Eligible patients had HER2-positive measureable MBC, with no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd89d1ff2270ca227f625aab499e6fcc
https://doi.org/10.1007/s10549-013-2551-9
https://doi.org/10.1007/s10549-013-2551-9
Autor:
Carey K. Anders, Eric P. Winer, Clifford A. Hudis, Katherine A. Hoadley, Lyndsay Harris, Ian E. Krop, William T. Barry, Brandelyn N. Pitcher, Donald A. Berry, Maggie C.U. Cheang, Lisa A. Carey, Norah Lynn Henry, Constance Cirrincione, Charles M. Perou, Michael D. Iglesia, David W. Ollila, Baljit Singh, Douglas Weckstein
Purpose Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0737f2439949512527a1f43c15b62506